QLI - Qilian International Holding Group Limited Debt to Book Capitalization Ratio

Brandmark of Qilian International (QLI)

Qilian International (QLI) generates revenue through the sale of veterinary antibiotics, licorice extracts, and pharmaceutical products. The current leverage ratio on the balance sheet from the GURU.Markets terminal is provided by a chart where 0.01 captures the current state of the parameter. Stability is ensured by delegating raw material procurement to farmers, while modern filtration and wastewater treatment systems guarantee the environmental sustainability of production.

qlsyy.net - QLI Debts to Book Capitalization (period 07/04/2022 - 08/17/2024)
Flagship merchandise of Qilian International Corp

Environmental regulatory pressure in China and heparin price volatility are increasing operating costs for Qilian International (QLI). This metric measures the share of total liabilities within the equity structure, determining the financial stability of assets. A declining ratio indicates increasing solvency and the minimization of credit risks. It is critical for investors to track the dynamics of debt coverage by net equity. By analyzing the correlation between debt size and balance sheet equity, one can assess the actual protection of the business.

Competitors of Qilian International

Debt to Book Capitalization Ratio Haleon plc|kenvue.com - Debt to Net Assets Ratio|VRNA: Debt to Book Capitalization Ratio|MENS - Debt to Book Value|LGND: Debts to Book Capitalization|Debts to Book Capitalization Amneal Corp|PRGO - Debt to Book Value|Debt to Net Assets Ratio ALVO|Liquidia - Debt to Book Capitalization Ratio|Debts to Book Value Galapagos N.V. GLPG|Debt to Book Value ANI Pharma (ANIP)|Debt to Book Capital Afrezza MNKD|Debts to Book Capitalization Amphastar Pharmaceuticals (AMPH)|PCRX - Debt to Net Assets Ratio|Debts to Book Capitalization SPRY|TBPH (Theravance Biopharma Inc) - Debts to Book Value|AQST - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SCPH|TECX: Debt to Book Capitalization Ratio|Debt to Net Assets tonixpharma.com (TNXP)|Debts to Book Capitalization SXTC|Eupraxia Pharmaceuticals, Inc. - Debts to Net Assets|BHST - Debt to Book Capitalization Ratio|EXOZ - Debt to Book Capitalization Ratio|oramed.com - Debts to Book Capitalization|Entera Bio (ENTX) - Debts to Net Assets|HYFT (MindWalk Holdings Inc.) - Debts to Book Capitalization|Debts to Book Capitalization ABVC|Debt to Book Capitalization Ratio Cumberland Pharma CPIX|Debt to Book Value Ratio Quantum BioPharma Corp QNTM|Debt to Book Value FibroGen, Inc.|Debt to Net Assets Ratio telomirpharma.com TELO|Debts to Book Capitalization RANI (Rani Therapeutics Inc)|SNYR: Debts to Net Assets|Debt to Book Capitalization Ratio rallybio.com|Debt to Book Value Ratio Lexaria Bioscience Corp.|Pulmatrix, Inc. (PULM) - Debt to Book Value|Debt to Book Capital Pheton|Aptorum Group Limited - Debts to Book Capitalization|Debts to Book Value LYRA (Lyra Therapeutics Inc.)|Debt to Book Capitalization Ratio Impact BioMedical Inc|TNF Pharmaceuticals Inc. - Debt to Net Assets Ratio|cbdMD Corp (YCBD) - Debt to Book Capitalization Ratio|PRFX - Debt to Book Value Ratio|CYTO: Debts to Book Capitalization|Debts to Book Capitalization Lipella Pharmaceuticals Inc|Optinose (OPTN) - Debt to Book Value|Debt to Book Capital Pieris Pharma|PROC (Procaps Group S.A.) - Debts to Book Capitalization|Debts to Net Assets PTPI (petrospharma.com)|SLRN: Debt to Book Capitalization Ratio|TFF Pharmaceuticals Inc. - Debts to Book Value